Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
100 Clinical Results associated with Polynoma LLC
0 Patents (Medical) associated with Polynoma LLC
100 Deals associated with Polynoma LLC
100 Translational Medicine associated with Polynoma LLC